STOCKSCOUTER

StockScouter Premium

StockScouter Screener and Portfolios are now in our premium offering.
Learn more or Get it now! Stockscouter Portfolio performance

JNJ JOHNSON & JOHNSON StockScouter® Report

6

StockScouter® Score

JOHNSON & JOHNSON, a large cap growth company in the healthcare sector, is expected to slightly outperform the market over the next six months with less than average risk

10 is the best possible rating. Learn more.

Summary

Positives

  • Short-term relative price momentum exhibits meaningful strength. Postive
  • One or more less experienced analysts has modestly increased quarterly earnings estimates for JNJ. Positive/Neutral

 

Concerns

  • The enterprise value-to-sales ratio is higher than the average for comparably-sized companies in the StockScouter universe. Negative
  • The ratio of JNJ’s forward price-to-earnings multiple to its estimated growth rate is above the average of comparably-sized companies in the StockScouter universe. Negative

 

Short-term Outlook

Over the next 1-2 months, StockScouter forecasts that large cap stocks will be in favor, growth stocks will be in favor, and healthcare stocks will be in favor.

Expected Risk/Return

Progress: 20% done.
Progress: 80% done.
Low
High

Core Model Grades

B
B
D
C

Previous Ratings

6
5
9